Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CSTL Castle Biosciences	$20.29 +1.4%	$18.00	$15.45 ▼ $35.84	$585.63M	1.1	425,387 shs	166,047 shs
FLGT Fulgent Genetics	$20.06 -0.2%	$20.07	$14.57 ▼ $25.11	$610.63M	1.03	286,106 shs	87,746 shs
PSNL Personalis	$7.56 +0.6%	$5.29	$1.20 ▼ $7.79	$667.26M	1.95	1.14 million shs	1.04 million shs
XGN Exagen	$6.74 -3.4%	$6.70	$1.71 ▼ $7.95	$143.46M	1.58	136,220 shs	227,319 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CSTL Castle Biosciences	+1.37%	+2.71%	+21.39%	+9.24%	-4.54%
FLGT Fulgent Genetics	-0.20%	+2.35%	-5.24%	+18.98%	+0.65%
PSNL Personalis	+0.60%	+18.60%	+54.82%	+142.93%	+534.87%
XGN Exagen	-3.37%	-3.65%	-8.86%	+67.12%	+272.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CSTL Castle Biosciences	3.0796 of 5 stars	3.5	4.0	0.0	2.6	2.5	0.0
FLGT Fulgent Genetics	3.3348 of 5 stars	2.3	1.0	4.1	1.2	3.3	0.6
PSNL Personalis	3.3733 of 5 stars	1.5	3.0	4.2	2.4	2.5	0.6
XGN Exagen	3.6633 of 5 stars	2.5	3.0	4.5	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CSTL Castle Biosciences	3.00	Buy	$37.00	82.40% Upside
FLGT Fulgent Genetics	2.50	Moderate Buy	$24.00	19.64% Upside
PSNL Personalis	3.00	Buy	$7.67	1.48% Upside
XGN Exagen	3.00	Buy	$7.50	11.36% Upside

Current Analyst Ratings Breakdown

Latest XGN, FLGT, PSNL, and CSTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	CSTL Castle Biosciences	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$44.00 ➝ $40.00
5/15/2025	XGN Exagen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	PSNL Personalis	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/15/2025	XGN Exagen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $7.00
5/13/2025	XGN Exagen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/7/2025	XGN Exagen	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/7/2025	PSNL Personalis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00
5/6/2025	FLGT Fulgent Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$16.00 ➝ $23.00
5/6/2025	CSTL Castle Biosciences	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $35.00
5/6/2025	CSTL Castle Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $37.00
5/5/2025	FLGT Fulgent Genetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$24.00 ➝ $25.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CSTL Castle Biosciences	$332.07M	1.76	$1.00 per share	20.34	$16.28 per share	1.25
FLGT Fulgent Genetics	$283.47M	2.15	N/A	N/A	$36.92 per share	0.54
PSNL Personalis	$84.61M	7.89	N/A	N/A	$2.87 per share	2.63
XGN Exagen	$56.72M	2.53	N/A	N/A	$0.54 per share	12.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CSTL Castle Biosciences	$18.25M	-$0.19	N/A	N/A	N/A	-1.46%	3.41%	2.95%	8/4/2025 (Estimated)
FLGT Fulgent Genetics	-$42.71M	-$1.33	N/A	N/A	N/A	-13.94%	-2.19%	-2.02%	8/1/2025 (Estimated)
PSNL Personalis	-$81.28M	-$1.29	N/A	N/A	N/A	-98.10%	-48.78%	-34.70%	8/6/2025 (Estimated)
XGN Exagen	-$15.11M	-$0.84	N/A	N/A	N/A	-27.34%	-133.69%	-34.87%	8/4/2025 (Estimated)

Latest XGN, FLGT, PSNL, and CSTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q2 2025	FLGT Fulgent Genetics	-$0.23	N/A	N/A	N/A	$76.21 million	N/A
5/12/2025	Q1 2025	XGN Exagen	-$0.20	-$0.20	N/A	-$0.20	$14.55 million	$15.50 million
5/6/2025	Q1 2025	PSNL Personalis	-$0.23	-$0.18	+$0.05	-$0.18	$17.41 million	$20.61 million
5/5/2025	Q1 2025	CSTL Castle Biosciences	-$0.08	-$0.20	-$0.12	-$0.90	$80.40 million	$87.99 million
5/2/2025	Q1 2025	FLGT Fulgent Genetics	-$0.18	$0.04	+$0.22	-$0.37	$71.26 million	$73.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CSTL Castle Biosciences	N/A	N/A	N/A	N/A	N/A
FLGT Fulgent Genetics	N/A	N/A	N/A	N/A	N/A
PSNL Personalis	N/A	N/A	N/A	N/A	N/A
XGN Exagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CSTL Castle Biosciences	0.02	9.37	9.19
FLGT Fulgent Genetics	N/A	6.32	6.32
PSNL Personalis	N/A	6.91	6.74
XGN Exagen	2.87	2.32	2.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CSTL Castle Biosciences	92.60%
FLGT Fulgent Genetics	48.06%
PSNL Personalis	61.91%
XGN Exagen	75.25%

Insider Ownership

Company	Insider Ownership
CSTL Castle Biosciences	6.50%
FLGT Fulgent Genetics	31.76%
PSNL Personalis	3.80%
XGN Exagen	12.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CSTL Castle Biosciences	540	28.87 million	27.00 million	Optionable
FLGT Fulgent Genetics	1,313	30.44 million	20.78 million	Optionable
PSNL Personalis	400	88.32 million	84.97 million	Optionable
XGN Exagen	220	21.30 million	18.62 million	Optionable

XGN, FLGT, PSNL, and CSTL Headlines

Recent News About These Companies

Exagen Insider Ups Holding During Year

June 29, 2025 | finance.yahoo.com

2025-06-23 | Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics | NDAQ:XGN | Press Release - Stockhouse

June 24, 2025 | stockhouse.com

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

June 23, 2025 | globenewswire.com

Exagen announces resale of up to 1.15M shares

June 20, 2025 | msn.com

Cantor Fitzgerald Estimates Exagen FY2026 Earnings

June 13, 2025 | marketbeat.com

Exagen Inc. Holds 2025 Annual Stockholder Meeting

June 11, 2025 | tipranks.com

Exagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Call Transcript

May 11, 2025 | insidermonkey.com

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

May 9, 2025 | finance.yahoo.com

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

May 9, 2025 | globenewswire.com

Exagen Inc. Prices Public Offering of Common Stock

May 8, 2025 | globenewswire.com

KeyBanc maintains Exagen stock at Sector Weight

May 7, 2025 | investing.com

KeyBanc maintains Exagen stock at Sector Weight

May 7, 2025 | investing.com

Exagen Inc. Announces Proposed Public Offering of Common Stock

May 7, 2025 | globenewswire.com

Earnings call transcript: Exagen Inc. Q1 2025 revenue beats forecasts, stock dips

May 6, 2025 | uk.investing.com

Exagen Inc. Reports Record Revenue Amid Strategic Growth

May 5, 2025 | tipranks.com

Exagen Inc. Earnings Call Highlights Record Growth

May 5, 2025 | tipranks.com

Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

May 5, 2025 | seekingalpha.com

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

May 5, 2025 | zacks.com

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

May 5, 2025 | globenewswire.com

Exagen Inc (XGN) Q1 2025 Earnings Report Preview: What To Expect

May 3, 2025 | finance.yahoo.com

Perceptive Advisors Enters $75MM Term Loan Facility with Exagen

April 29, 2025 | abladvisor.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN, FLGT, PSNL, and CSTL Company Descriptions

Castle Biosciences NASDAQ:CSTL

$20.28 +0.28 (+1.37%)

As of 07/3/2025 01:04 PM Eastern

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Fulgent Genetics NASDAQ:FLGT

$20.06 -0.04 (-0.20%)

Closing price 07/3/2025 02:30 PM Eastern

Extended Trading

$20.06 0.00 (0.00%)

As of 07/3/2025 04:32 PM Eastern

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Personalis NASDAQ:PSNL

$7.56 +0.05 (+0.60%)

Closing price 07/3/2025 03:36 PM Eastern

Extended Trading

$7.48 -0.08 (-1.06%)

As of 07/3/2025 04:47 PM Eastern

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Exagen NASDAQ:XGN

$6.74 -0.24 (-3.37%)

As of 07/3/2025 02:54 PM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time